Legal Notice

Information pursuant to § 5 TMG

TICEBA GmbH
Tissue & Cell Banking
Im Neuenheimer Feld 517
69120 Heidelberg, Germany

Represented by

TICEBA GmbH, represented by the managing director Dr. Christoph Ganss.

Contact

T +49 6221 71833-0
F +49 6221 71833-29
E office@ticeba.com
W www.ticeba.com

Register entry

Entry in the Handelsregister.
Registering court: Amtsgericht Mannheim
Registration number: HRB 337564

VAT ID

Sales tax identification number according to § 27 a of the Sales Tax Law:
DE231465237

Responsible for the content according to § 55(2) RStV

Dr. Christoph Ganss
Im Neuenheimer Feld 517
69120 Heidelberg, Germany

Web Realisation & Administration

COM-STYLE | Johannes Döring
Email: info@com-style.com
Homepage: www.com-style.de

FH-Webservices | Florian Hilmes
Email: info@fh-webservices.de
Homepage: www.fh-webservices.de

Web Design

Melters Werbeagentur GmbH
Email: info@melters-werbeagentur.com
Homepage: www.melters-werbeagentur.com

EU dispute resolution

The European Commission provides a platform for online dispute resolution (ODR): https://ec.europa.eu/consumers/odr.
Our email address can be found above in the legal notice. We are not willing or obliged to participate in dispute resolution proceedings before a consumer arbitration board.



Disclaimer

Liability for Contents

As service providers, we are liable for own contents of these websites according to Sec. 7, paragraph 1 German Telemedia Act (TMG). However, according to Sec. 8 to 10 German Telemedia Act (TMG), service providers are not obligated to permanently monitor submitted or stored information or to search for evidences that indicate illegal activities.

Legal obligations to removing information or to blocking the use of information remain unchallenged. In this case, liability is only possible at the time of knowledge about a specific violation of law. Illegal contents will be removed immediately at the time we get knowledge of them.

Liability for Links

Our offer includes links to external third party websites. We have no influence on the contents of those websites, therefore we cannot guarantee for those contents. Providers or administrators of linked websites are always responsible for their own contents.

The linked websites had been checked for possible violations of law at the time of the establishment of the link. Illegal contents were not detected at the time of the linking. A permanent monitoring of the contents of linked websites cannot be imposed without reasonable indications that there has been a violation of law. Illegal links will be removed immediately at the time we get knowledge of them.

Copyright

Contents and compilations published on these websites by the providers are subject to German copyright laws. Reproduction, editing, distribution as well as the use of any kind outside the scope of the copyright law require a written permission of the author or originator. Downloads and copies of these websites are permitted for private use only. The commercial use of our contents without permission of the originator is prohibited.

Copyright laws of third parties are respected as long as the contents on these websites do not originate from the provider. Contributions of third parties on this site are indicated as such. However, if you notice any violations of copyright law, please inform us. Such contents will be removed immediately.



Copyright Information

The copyright for any material created by the TICEBA GmbH is reserved. Any duplication or use of objects such as texts, diagrams, graphics, photos, videos, etc. in other electronic or printed publications is not permitted without the agreement by the TICEBA GmbH.


Photo licences

Photo ID: 23788640 © Robert Kneschke - Fotolia.com
Photo ID: 8653783 © Monkey Business - Fotolia.com
Photo ID: 11005588 © cphoto - Fotolia.com
Photo ID: 34443496 © CLIPAREA.com - Fotolia.com
Photo ID: 44655286 © CLIPAREA.com - Fotolia.com
Photo ID: 21975848 © CLIPAREA.com - Fotolia.com
Photo ID: 41785433 © CLIPAREA.com - Fotolia.com
Photo ID: 34870095 © CLIPAREA.com - Fotolia.com
Photo ID: 42315218 © Sagittaria - Fotolia.com
Photo ID: 49608307 © Sebastian Kaulitzki - Fotolia.com
Photo ID: 44777469 © ag visuell - Fotolia.com
Photo ID: 39549962 © bilderzwerg - Fotolia.com
Photo ID: 183855418 © DNY59 - istockphoto.com
Photo ID: 157742328 © luismmolina - istockphoto.com
Photo ID: 162264253 © nicolas_ - istockphoto.com

News
Coronavirus and Mesenchymal Stem Cells

Therapy for Pneumonia Patients infected by 2019 Novel Coronavirus

Treatment With Mesenchymal Stem Cells for Severe Corona Virus Disease 2019(COVID-19)

Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With 2019 Novel Coronavirus

Article about our study with limbal stem cells

On the website of the Harvard Stem Cell Institute you will find the following news release about the ongoing clinical trial conducted by our daughter company RHEACELL in patients suffering from limbal stem cell deficiency: Restoring vision: A stem cell therapy for cornea regeneration reaches the clinical-trial stage.

Clinical Trial - EB

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and several European competent national regulatory authorities. The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) for the treatment of EB.

Clinical Trial - LSCD

The international phase I/IIa clinical trial has been approved by the U.S. Food and Drug Administration (FDA) and the German regulatory authority (Paul Ehrlich Institute). The medicinal drug product tested in this trial has recently been granted Orphan Drug designation from the FDA and the European Medicines Agency (EMA) and Fast Track designation from the FDA for the treatment of LSCD.

Safety

In a comprehensive preclinical study program, safety and local tolerability of ABCB5+ MSCs following subcutaneous, intramuscular and intravenous application has been demonstrated (Tappenbeck et al., 2019).

Newsletter